Genomic Vision
First-half 2022 Results
Regulatory News:
Genomic Vision (the “Company” - FR0011799907 – GV), a biotechnology company that develops tools and services dedicated to the analysis and control of changes in the genome, today announces its half-year financial results to June 30th, 20221. The H1 financial report is available in the Investors section of Genomic Vision’s website.
H1 2022 results
(in € thousands – IFRS) |
H1 2022 |
H1 2021 |
||
Revenue from sales |
511 |
467 |
||
Other revenue |
232 |
235 |
||
Total revenue from activity |
743 |
702 |
||
Current operating expenses |
(3,197) |
(3,066) |
||
Current operating loss |
(2,454) |
(2,364) |
||
Other operating expenses / income |
(57) |
50 |
||
Operating loss |
(2,510) |
(2,314) |
||
Cost of financial debt and other financial expenses / income |
(40) |
(15) |
||
Net loss |
(2,568) |
(2,329) |
Revenue from sales totaled €511 thousand in the first half of 2022, growing by 9.4% compared with the first half of 2021. This growth was achieved by a more consolidated commercial offer,
improvements in logistics and customer management, and by the sale of a scanner to the University of South Florida.
Total revenue from activity, once other revenue is taken into account, grew by 5.8% to €743 thousand. Other revenue, corresponding to the Research Tax Credit, was €232 thousand.
Lesen Sie auch
Current operating expenses grew by 4.3% to €3.2 million, and principally broke down as follows, in addition to the cost of sales: